Author: Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS
Source: International Journal of Implant Dentistry
Year: 2019
Comment:
Abstract / Excerpt:
BACKGROUND:
Medication-related osteonecrosis of the jaw (MRONJ) is characterized by the development of bone necrosis in the jaws of patients receiving antiresorptive and/or antiangiogenic medications. No scientific reports have been published yet on bevacizumab-related osteonecrosis of the jaw (BeRONJ) when associated with dental implant placement and adjuvant ozone therapy.
CASE PRESENTATION:
A 54-year-old female patient with a history of metastatic breast cancer and bevacizumab use presented with a dental infection. Dental extraction followed immediately by dental implant placement was planned after suspension of the bevacizumab treatment. The patient presented with pain, drainage of purulent secretion, and bone exposure 5 weeks post-surgery. Complete healing was achieved at postoperative 7 months.
CONCLUSIONS:
The combination of adjuvant ozone therapy and surgical debridement was effective for the treatment of MRONJ; however, the risk of MRONJ may persist after the suspension of bevacizumab for 28 days.
Citation: Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. International Journal of Implant Dentistry. 2019;5(1):1-6.